Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy - Centre de recherche des Cordeliers Access content directly
Journal Articles International review of cell and molecular biology / Int Rev Cell Mol Biol Year : 2024

Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy

Abstract

Since the dawn of anticancer immunotherapy, the clinical use of immune checkpoint inhibitors (ICI) has increased exponentially. Monoclonal antibodies targeting CTLA-4 and the PD-1/PD-L1 interaction were first introduced for the treatment of patients with unresectable melanoma. In melanoma, ICI lead to durable regression in a significant number of patients and have thus been clinically approved as a first-line treatment of advanced disease. Over the past years an increasing number of regulatory approvals have been granted for the use of ICI in patients affected by a large range of distinct carcinomas. In retrospect surprisingly, it has been discovered that particularly successful chemotherapeutic treatments are able to trigger anticancer immune responses because they induce immunogenic cell death (ICD), hence killing cancer cells in a way that they elicit an immune response against tumor-associated antigens. Logically, preclinical studies as well as clinical trials are currently exploring the possibility to combine ICD inducers with ICI to obtain optimal therapeutic effects. Here, we provide a broad overview of current strategies for the implementation of combinatorial approaches involving ICD induction followed by ICI in anticancer therapy.
Fichier principal
Vignette du fichier
Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy.pdf (1.13 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04601417 , version 1 (04-06-2024)

Identifiers

Cite

Hui Pan, Peng Liu, Guido Kroemer, Oliver Kepp. Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy. International review of cell and molecular biology / Int Rev Cell Mol Biol, 2024, International Review of Cell and Molecular Biology, 382, pp.279-294. ⟨10.1016/bs.ircmb.2023.06.001⟩. ⟨hal-04601417⟩
18 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More